"Performance" Dongyao Pharmaceutical reported a full-year loss of 100 million yuan, turning from profit to loss
Dongyao Pharmaceutical-B (01875.HK) announced its performance for the fiscal year 2025, with operating revenue of 748 million RMB, a year-on-year decrease of 32%. Among this, product sales revenue was 488 million RMB, down 44%, mainly due to intensified market competition. It recorded a loss of 100 million RMB, compared to a net profit of 34.76 million RMB in the previous year, turning from profit to loss; loss per share was 14 cents. No dividend was declared
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments